NASDAQ:OCUL Ocular Therapeutix (OCUL) Stock Price, News & Analysis $8.39 -0.05 (-0.59%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$8.13▼$8.5350-Day Range$6.45▼$9.2352-Week Range$2.00▼$11.31Volume584,071 shsAverage Volume2.05 million shsMarket Capitalization$1.30 billionP/E RatioN/ADividend YieldN/APrice Target$15.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Ocular Therapeutix alerts: Email Address Ocular Therapeutix MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside86.7% Upside$15.67 Price TargetShort InterestBearish12.12% of Shares Sold ShortDividend StrengthN/ASustainability-2.01Upright™ Environmental ScoreNews Sentiment0.24Based on 5 Articles This WeekInsider TradingSelling Shares$16,525 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.02) to ($0.97) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.56 out of 5 starsMedical Sector241st out of 910 stocksPharmaceutical Preparations Industry104th out of 426 stocks 3.4 Analyst's Opinion Consensus RatingOcular Therapeutix has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageOcular Therapeutix has only been the subject of 4 research reports in the past 90 days.Read more about Ocular Therapeutix's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted12.12% of the outstanding shares of Ocular Therapeutix have been sold short.Short Interest Ratio / Days to CoverOcular Therapeutix has a short interest ratio ("days to cover") of 10.3, which indicates bearish sentiment.Change versus previous monthShort interest in Ocular Therapeutix has recently decreased by 1.68%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldOcular Therapeutix does not currently pay a dividend.Dividend GrowthOcular Therapeutix does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreOcular Therapeutix has received a 57.83% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Ophthalmologicals (S01)" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Ocular Therapeutix is -2.01. Previous Next 2.4 News and Social Media Coverage News SentimentOcular Therapeutix has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Ocular Therapeutix this week, compared to 4 articles on an average week.Search Interest23 people have searched for OCUL on MarketBeat in the last 30 days. This is an increase of 77% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Ocular Therapeutix to their MarketBeat watchlist in the last 30 days. This is a decrease of -29% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ocular Therapeutix insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $16,525.00 in company stock.Percentage Held by InsidersOnly 5.50% of the stock of Ocular Therapeutix is held by insiders.Percentage Held by Institutions59.21% of the stock of Ocular Therapeutix is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ocular Therapeutix's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ocular Therapeutix are expected to grow in the coming year, from ($1.02) to ($0.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ocular Therapeutix is -6.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ocular Therapeutix is -6.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOcular Therapeutix has a P/B Ratio of 3.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Ocular Therapeutix's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Golden CrestBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.>> Get Your FREE Wealth Protection Guide << About Ocular Therapeutix Stock (NASDAQ:OCUL)Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.Read More OCUL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OCUL Stock News HeadlinesAugust 29, 2024 | insidertrades.comSanjay Nayak Sells 1,832 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) StockSeptember 5 at 8:58 AM | stockhouse.comOcular Therapeutix(TM) to Present at Two Investor Conferences in SeptemberSeptember 7, 2024 | Porter & Company (Ad)Trump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…September 5 at 8:58 AM | stockhouse.comOcular Therapeutix(TM) to Present at September Retina MeetingsSeptember 5 at 7:30 AM | globenewswire.comOcular Therapeutix™ to Present at September Retina MeetingsSeptember 4 at 7:30 AM | globenewswire.comOcular Therapeutix™ to Present at Two Investor Conferences in SeptemberAugust 31, 2024 | ca.finance.yahoo.comOCUL Jan 2025 2.500 callAugust 29, 2024 | markets.businessinsider.comBuy Rating Affirmed for Oculis Holdings Amid Strong Pipeline and Positive FDA FeedbackSeptember 7, 2024 | Porter & Company (Ad)Trump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…August 17, 2024 | ca.finance.yahoo.comOCUL Sep 2024 17.500 callAugust 9, 2024 | markets.businessinsider.comPositive Financial and Clinical Trials Outlook Solidifies Buy Rating for Ocular TherapeutixAugust 9, 2024 | markets.businessinsider.comPositive Outlook for Ocular Therapeutix: Buy Rating Affirmed Amidst FDA Alignment and Promising Trial ProgressAugust 9, 2024 | globenewswire.comOcular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 8, 2024 | finance.yahoo.comWith 65% ownership of the shares, Ocular Therapeutix, Inc. (NASDAQ:OCUL) is heavily dominated by institutional ownersAugust 7, 2024 | tmcnet.comOcular Therapeutix™ Announces FDA Feedback That SOL-R Trial is Appropriate as a Registrational Study in Wet AMDAugust 7, 2024 | finanznachrichten.deOcular Therapeutix, Inc.: Ocular Therapeutix Reports Second Quarter 2024 ResultsAugust 7, 2024 | markets.businessinsider.comBuy Rating Justified by Ocular Therapeutix’s Rapid SOL-1 Trial Progress and Positive FDA Feedback on SOL-RAugust 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Ocular Therapeutix Amid Positive Trial Developments and Strong Financial OutlookSee More Headlines Receive OCUL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ocular Therapeutix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/07/2024Today9/07/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:OCUL CUSIPN/A CIK1393434 Webwww.ocutx.com Phone(781) 357-4000Fax781-357-4001Employees230Year FoundedN/APrice Target and Rating Average Stock Price Target$15.67 High Stock Price Target$22.00 Low Stock Price Target$11.00 Potential Upside/Downside+86.7%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-80,740,000.00 Net Margins-226.46% Pretax Margin-226.46% Return on Equity-52.75% Return on Assets-31.74% Debt Debt-to-Equity Ratio0.18 Current Ratio16.64 Quick Ratio16.55 Sales & Book Value Annual Sales$61.10 million Price / Sales21.27 Cash FlowN/A Price / Cash FlowN/A Book Value$2.42 per share Price / Book3.47Miscellaneous Outstanding Shares154,889,000Free Float146,370,000Market Cap$1.30 billion OptionableOptionable Beta1.30 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Antony Mattessich (Age 56)President, CEO & Director Comp: $1.05MMr. Donald Notman Jr.Chief Financial OfficerDr. Jeffrey S. Heier M.D. (Age 63)Chief Scientific Officer Comp: $84.88kDr. Rabia Gurses Ozden M.D. (Age 55)Chief Medical Officer Comp: $621.39kDr. Pravin U. Dugel M.D. (Age 60)Executive Chairman Dr. Karen-Leigh Edwards M.B.A.Ph.D., Chief Operations OfficerDr. Peter K. Jarrett Ph.D. (Age 67)Chief Technology Officer Mr. Philip C. Strassburger Esq. (Age 64)General Counsel Comp: $282.61kMr. William H. Ransone IIVice President of Global Sales & MarketingMs. Tracy SmithVice President of Human ResourcesMore ExecutivesKey CompetitorsInnovivaNASDAQ:INVAArcutis BiotherapeuticsNASDAQ:ARQTPhathom PharmaceuticalsNASDAQ:PHATKiniksa PharmaceuticalsNASDAQ:KNSAPliant TherapeuticsNASDAQ:PLRXView All CompetitorsInsiders & InstitutionsSanjay NayakSold 1,832 sharesTotal: $16,524.64 ($9.02/share)Cetera Investment AdvisersBought 13,054 shares on 8/22/2024Ownership: 0.477%Nantahala Capital Management LLCBought 1,000,000 shares on 8/20/2024Ownership: 0.646%Point72 Asset Management L.P.Bought 2,706,663 shares on 8/19/2024Ownership: 1.736%Second Line Capital LLCBought 262,810 shares on 8/16/2024Ownership: 0.170%View All Insider TransactionsView All Institutional Transactions OCUL Stock Analysis - Frequently Asked Questions How have OCUL shares performed this year? Ocular Therapeutix's stock was trading at $4.46 on January 1st, 2024. Since then, OCUL stock has increased by 88.1% and is now trading at $8.39. View the best growth stocks for 2024 here. How were Ocular Therapeutix's earnings last quarter? Ocular Therapeutix, Inc. (NASDAQ:OCUL) posted its earnings results on Wednesday, August, 7th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.04. The company's quarterly revenue was up 7.9% on a year-over-year basis. Who are Ocular Therapeutix's major shareholders? Ocular Therapeutix's top institutional investors include Avoro Capital Advisors LLC (5.20%), Logos Global Management LP (3.32%), Point72 Asset Management L.P. (1.74%) and Deltec Asset Management LLC (1.67%). Insiders that own company stock include Summer Road Llc, Antony C Mattessich, Sanjay Nayak, Donald Notman, Philip C Strassburger, Christopher G White and Rabia Gurses Ozden. View institutional ownership trends. How do I buy shares of Ocular Therapeutix? Shares of OCUL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Ocular Therapeutix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ocular Therapeutix investors own include Clearside Biomedical (CLSD), Northwest Biotherapeutics (NWBO), Novavax (NVAX), Dynavax Technologies (DVAX), Omeros (OMER) and Gilead Sciences (GILD). This page (NASDAQ:OCUL) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocular Therapeutix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocular Therapeutix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
